In order to fully implement the spirit of General Secretary Jin Ping’s important instructions on the network
Latest research progress of CRISPR/Cas in March 2021
Time of Update: 2021-04-19
1038/s41467-021-21559-9 Nat Commun: Scientists have developed new gene editing tools to correct human genetic diseases mutationImage source: Agency for Science, Technology and Research (A*STAR), Genome Institute of Singapore (GIS).
Latest research progress of CRISPR/Cas in February 2021
Time of Update: 2021-03-27
Mol Cell: New gene editing technology allows CRISPR-Cas9 to edit DNA sequentially doi:10.
Shenkan CA | Current status and progress in the treatment of metastatic or unresectable gastric cancer
Time of Update: 2021-03-22
02 Other research progress Phase II KEYNOTE-059 study included patients with advanced gastric cancer after at least second-line treatment failure.
CA Cancer J Clin: 2020 U.S. Youth and Young Cancer Statistics Report
Time of Update: 2021-01-24
the incidence of breast cancer has increased by nearly 2% and 0.2% per year in women aged 20-29 and over 30 in the last decade, respectively, while the incidence rate among adolescents has been stable.
Heavy discovery | God's journal CA announces the reasons for the decline in cancer deaths in the United States!
Time of Update: 2021-01-23
same time, the overall death rate in the United States fell by 7.7 percent between 2014 and 2018, 46 percent of which was due to lung cancer.
The first in the country! Boya was approved for clinical treatment of thalassemia in the case of crispr/Cas 9 gene β gene editing therapy
Time of Update: 2021-01-22
ET-01, a generic self-contained CD34 plus hematocyte injection called CRISPR/Cas9 gene modification BCL11A red line enhancer, is an in-development, self-contained, in-body gene-edited cell therapy product for the treatment of transfusion-dependent type β threetic anemia.
The latest CRISPR/Cas research advances in December 2020
Time of Update: 2021-01-02
/> study was published in the December 11, 2020 issue of the journal Science under the title "CiBER-seq dissects genetic networks by quantitative CRISPRi profiling of expression phenotypes." the CiBER-seq principle diagram, pictured from Science
The prospects and ethics of CRISPR/Cas gene editing therapy are disputed
Time of Update: 2020-12-23
research in the development of genome editing methods. first published research on CRISPR/Cas gene editing technology in the prestigious journal Science in 2012, winning the Nobel Prize in Chemistry in just eight years, officially heralding the era
CA Cancer J Clin: For the first time, the system introduces the clinical application of circulating tumor DNA and its future direction
Time of Update: 2020-11-26
this review, the current and emerging applications of plasma ctDNA testing techniques in advanced solid tumor types are discussed, and the research methods that may be translated into clinical practice in the near future are highlighted.
The latest CRISPR/Cas research advances from August to September 2020.
Time of Update: 2020-10-14
short reply repeat sequences, and Cas is short for CRISPR-related proteins. crispr/Cas was originally found in bacteria, a defense against the invasion of antiphages and other pathogens. images from Thomas Splettstoesser (Wikipedia, CC
CA Cancer J Clin: Revealing the cruel truth that cancer is getting younger! The number of cancer
Time of Update: 2020-10-04
the age group 20-29, the incidence of cancer is 42 and 55 cases per 100,000 population, respectively, and the incidence of cancer among women is 30 per cent higher than that of men.
Analysis of C2c1 crystal structure in CRISPR-Cas system.
Time of Update: 2020-09-14
The CRISPR-Cas system consists of clusters of regularly spaced short echo repetition sequences and its associated proteins (Cas), which are RNA-mediated accessary immune systems in primary nuclear organisms and whose primary function is to protect
Zhang Feng: CRISPR-Cas system classification map.
Time of Update: 2020-09-12
, based on different family of effect proteins, class 1 CRISPR-Cas systems are divided into three types (I, III, IV) and 12 subsypes (see figure below), according to the paper.
Zhang Feng's latest Cell sub-article: Two new CRISPR-Cas systems.
Time of Update: 2020-09-12
In a recent paper, a team led by Zhang Feng, a well-known CRISPR research pioneer, used computational sequence database mining to discover two class II CRISPR-Cas systems, subtype VI-B, which lack Cas1 and Cas2, contain a single large-scale effect
Advances in the study of the structure of cas13a (also known as C2c2), a VI-type CRISPR-Cas system-effect protein.
Time of Update: 2020-08-27
On July 27th Cell, a leading international journal, published online new advances made by Wang Yanli and Zhang Xinzheng of the Institute of Biophysics of the Chinese Academy of Sciences in the structural study of the VI-TYPE CRISPR-Cas system-effect